Matt Dankner

@McGillMed IntMed, incoming MedOnc Resident
@McGill_MDPhD
@McGillGCI Bench↔Bedside, Brain Mets
Aspiring Oncologist-Scientist
Most importantly- Dad, Husband 👪

[Matt Dankner @MDankner]

@gelarehzadeh @MayoClinic @UHN @MayoPlatform @ap_landry @FarshadNassiri @Kenneth_Aldape @BrainTumourOrg @CIHR_IRSC Beautiful work @gelarehzadeh ! Sorry to contact you in this way, I think my replies to your emails are all still going to spam for some reason.

[Mark Lewis, MD, FASCO @marklewismd]

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer

Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived

#ASCO26

[Matt Dankner @MDankner]

Huge thanks to all of our co-authors, including Sr. Author Dr. Peter Siegel @McGillGCI, Veronique Ouellet @CRCHUM, Jakob Lafon @McGillMed, Matt Annis, @rima_ezz & @Afnan_AAT ! @McGill_MDPhD @oncopole
@OncoAlert

[Matt Dankner @MDankner]

Pleased to share our latest publication in @BCRJournal @SpringerNature !

https://t.co/3ZAXdV0MwH

In 2021 we discovered that CIRBP plays an important role in the invasive growth of brain mets; we wondered if it also plays a role in metastasis more broadly 🤔

[Matt Dankner @MDankner]

This finding highlights the subtype-specific prognostic significance of CIRBP in breast cancer and suggests differential underlying mRNA targets bound and modulated by CIRBP in TNBC and HR + tumors, respectively.

More on this to come in amazing fundamental work by @rima_ezz !

[Dr Sarah Sammons @drsarahsam]

Study that went under the radar at ASCO.

WBRT with hippocampal sparing and memantine versus SRS for 5-20 brain metastases.

Same Overall survival, Lower Symptom Burden and Life Interference with SRS, Better KPS with SRS. New standard of care! Congrats Dr. Aizer on this amazing IST.

Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial. | Journal of Clinical Oncology

@DFCI_BreastOnc @OncoAlert #bcsm

[Matt Dankner @MDankner]

@RussellYanofsky @IBDMD @amelia_kellar @KrugCleveland @Klein_Jeremy @IBDPharmD @ashershaf A very productive fellowship !!!!

[Jonathan Spicer MD PhD @DoctorJSpicer]

Check out this awesome new study by the spatial biologists @McGillGCI led by @LysDesharnais @sorin_mark and PI @loganawalsh! Few studies provide such detail contrasting the spatial TME of LUSC and LUAD: the two dominant NSCLC histologies! https://t.co/cYevy0n2Gj

[Katarzyna Jerzak, MD, MSc, FRCPC @JerzakKasia]

Congrats to @KAhmedMD & team on this important brain mets screening study!

The cumulative incidence of brain mets among pts with HR+/HER2-ve mbc whose dz progressed on 1st line ET was quite high (23% @ 6 mo) & comparable to that of pts with HER2+ (24%) and triple neg mbc (25%).

[Matt Dankner @MDankner]

Huge thanks to our co-authors from near and far, those on here include ➡️ @EmmaJRousselle @ANowakowski11 @annalazaratos @NicolaNormanno @ArielleElkrief @MLadanyi @DrDrAprilRose @LDI_ILD @McGillGCI

[Matt Dankner @MDankner]

We are excited to share our latest publication "Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers", out today in @JCOPO_ASCO !

https://t.co/zoDmQRHcZ0

[Matt Dankner @MDankner]

Our data suggests that Class 2 MAP2K1 mt tumors are in a sweet spot to derive benefit from MEK inhibitors, perhaps due to less reliance on upstream mts while also retaining sensitivity to approved MEK inhibitors. We hope that this data can inform Molecular TBs and future trials!

[OncoAlert @OncoAlert]

Machine learning prediction of brain metastasis invasion pattern on brain magnetic resonance imaging scans Out on NeuroOncology Advances

https://t.co/R8DhhSUZsj

Brain metastasis invasion pattern (BMIP) is a valuable biomarker linked to survival outcomes and therapeutic responses, but currently requires histopathological examination of surgical specimens. This study aimed to explore the potential of machine learning (ML) to develop a noninvasive MRI-based biomarker for BMIP. Out of 329 patients, 132 met the study's inclusion criteria. While expert neuroradiologists struggled to predict BMIP from MRI scans (accuracy 44%-59%), ML models, including convolution-based deep learning (CDL), achieved significantly higher performance. The best model reached an accuracy of 85% and an F1 score of 90%, suggesting ML could offer a reliable, noninvasive method to predict BMIP and guide patient management.

@ANowakowski11
@tariq_dh
@JWongggMD
@MDankner

[Anna Lazaratos @annalazaratos]

Check out our latest article in @CurrentOncology on real-world data for HER2+ and HER2-low BC patients receiving TDXd and its effectiveness in those with brain and leptomeningeal metastases. https://t.co/AW0xCP0PNF